Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
16.49
+0.97 (6.25%)
At close: Oct 29, 2026, 4:00 PM EDT
15.73
-0.76 (-4.61%)
After-hours: Oct 29, 2026, 7:54 PM EDT
Biohaven Employees
Biohaven had 274 employees as of December 31, 2025. The number of employees increased by 18 or 7.03% compared to the previous year. That makes Biohaven the 24,540th largest employer in the world and 3,141st in the United States.
Employees
274
Change (1Y)
18
Growth (1Y)
7.03%
Revenue / Employee
n/a
Profits / Employee
-$1,980,573
Market Cap
2.49B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 274 | 18 | 7.03% |
| Dec 31, 2024 | 256 | 17 | 7.11% |
| Dec 31, 2023 | 239 | 37 | 18.32% |
| Dec 31, 2022 | 202 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Agios Pharmaceuticals | 540 |
| Maravai LifeSciences Holdings | 415 |
| Vera Therapeutics | 361 |
| Harmony Biosciences Holdings | 293 |
| Xencor | 260 |
| Celldex Therapeutics | 198 |
| Precigen | 160 |
BHVN News
- 10 hours ago - Biohaven reports Q3 adjusted EPS (73c) vs. ($1.47) last year - TheFly
- 10 hours ago - Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results - PRNewsWire
- 19 hours ago - Biohaven Quarterly report: Q3 2026 - Filings
- 19 hours ago - Biohaven Earnings release: Q3 2026 - Filings
- 3 days ago - Biohaven presents preclinical data for novel TRAP degrader at ASN Kidney Week - TheFly
- 3 days ago - Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy - PRNewsWire
- 6 days ago - Biohaven price target raised to $22 from $19 at RBC Capital - TheFly
- 6 days ago - Biohaven price target raised to $48 from $42 at Baird - TheFly